Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: Lack of a polymorphism in CYP1A2 in Caucasians

Pharmacogenetics

Volumn 9, Issue 3, 1999, Pages 367-375

  Welfare, Mark R ^a,b   Aitkin, Murray ^a   Bassendine, Margaret F ^a   Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Caffeine; CYP1A2; Genetic polymorphism

Indexed keywords

CAFFEINE; CYTOCHROME P450 ISOENZYME; DNA; PARAXANTHINE;

ADULT; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DNA SEQUENCE; DRUG METABOLISM; ENVIRONMENTAL FACTOR; EXON; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM LIKELIHOOD METHOD; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SMOKING;

EID: 0032810704     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199906000-00012     Document Type: Article

References (35)

1. Aitkin M, Anderson DA, Francis BJ, Hinde JP. Statistical modelling in GLIM. Oxford: Oxford University Press, 1989.
2. Arnaud MJ, Welsch C. Theophylline and caffeine metabolism in man. In: Rietbrock N, Woodcock BG, Staib AH, eds. Theophylline and other methylxanthines. Braunschweig: Vieweg Verlag, 1982; 135-148.
3. Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riche C, Guillouzo. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 1990; 19:561-567.
4. Bertilsson L, Carrillo JA, Dahl M-L, LLerena A, Alm C, Bondesson U, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38:471-473.
5. Bland M (ed). An introduction to medical statistics. Oxford: Oxford Medical Publications, 1987.
6. Bonati M, Latini R, Galleti F, Young JF, Tognoni JF, Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther 1982; 32:98-106.
7. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450 1A (1A2) the phenacetin O-deethylase is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic amines. Proc Natl Acad Sci USA 1989; 86:7696-7700.
8. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2:116-127.
9. Carrillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994; 55:293-304.
10. Catteau A, Bechtel YC, Poisson N, Bechtel PR, Bonaiti-Pellie C. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995; 47:423-430.
11. Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multiallelism. Meth Enzymol 1996; 272:199-210.
12. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4:109-116.
13. Fuhr U, Doehmer J, Battula N, Wolfel C, Kudla C, Keita Y, Staib AH. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 enzymes. Biochem Pharmacol 1992; 43:225-235.
14. Fuhr U, Engelhardt R, Sachs M, Rost KL, Schymanski P, Huschka C, et al. Human CYP1A2 activity: relationship between caffeine clearance in vivo and its 3-demethylation in vitro [abstract]. Paper presented at the 8th International Conference on Cytochrome P450. Gulbenkian Institute of Science: Lisbon 1993; 202.
15. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping by in vivo versus in vitro correlations. Pharmacogenetics 1996; 6:159-176.
16. Grant DM, Tang BK, Kalow W. Variability of caffeine metabolism. Clin Pharmacol Ther 1983; 33:591-602.
17. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2:73-77.
18. Ikeya K, Jaiwal AK, Owena RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous genes and differences in liver 1A2 mRNA expression. Molec Endocrinol 1989; 3:1399-1407.
19. Ito N, Hasegawa R, Sano M, Tamano S, Esumi H, Takayama S, Sugimura T. A new colon and mammary carcinogen in cooked food, PhIP. Carcinogenesis 1991; 12:1503-1506.
20. Iwahana H, Yoshimoto K, Mizusawa N, Kudo E, Itakura M. Multiple fluorescence-based PCR-SSCP analysis. Biotechniques 1994; 16:296-297.
21. 3450 cDNA and complete amino-acid sequence. Nucl Acids Res 1986; 14:6773-6774.
22. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50:508-519.
23. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, Hauer-Jensen M, Kadlubar FF. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer and polyps. Cancer Epidemiol Biomark Prev 1994; 3:675-682.
24. Lelo A, Miners JO, Robson RA, Birkett DJ. Quantitative assessment of caffeine partial clearance in man. Br J Pharmacol 1986; 22:183-186.
25. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, et al. The major pathway of imipramine is catalysed by cytochromes P-450 1A2 and 3A4 in human liver. Mol Pharmacol 1993; 43:827-832.
26. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomark Prev 1994; 3:413-421.
27. Quattrochi LC, Pendurthi UR, Okino ST, Potenza C, Tukey RH. Human cytochrome P-450 4 mRNA and gene: part of a multigene family that contains Alu sequences in its mRNA. Proc Natl Acad Sci USA 1986; 83:6731-6735.
28. Quattrochi LC, Vu T, Tukey RH. The human CYP1A2 gene and induction by 3-methylcholanthrene. J Biol Chem 1994; 269:6949-6954.
29. Ravnik-Glavac M, Glavac D, Dean M. Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene. Hum Mol Genet 1994; 3:801-807.
30. Sanger F, Niclen S, Coulsen AR. DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 1977; 74:5463-5467.
31. Skog K. Cooking procedures and food mutagens: a review of the literature. Fed Chem Toxic 1993; 9:655-675.
32. Sugimura T, Sato S. Mutagens-carcinogens in foods. Cancer Res 1983; 43:2415S-2421S.
33. Tang BK, Zhou Y, Kadar D, Kalow. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994; 4:117-124.
34. Tassaneeyakul W, Birkett DJ, McManus ME, Veronese ME, Andersson T, Tukey RH, Miners JO. Caffeine metabolism by human hepatic cytochrome P450: contributions of 1A2:2E1 and 3A isoforms. Biochem Pharmacol 1994; 47:1767-1776.
35. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13:1561-1568.